The role of molecular profiling in adrenocortical carcinoma

Juliane Lippert, Martin Fassnacht, Cristina Ronchi

Research output: Contribution to journalArticlepeer-review

50 Downloads (Pure)


Adrenocortical carcinoma (ACC) is a rare, aggressive cancer with still partially unknown pathogenesis, heterogenous clinical behaviour and no effective treatment for advanced stages. Therefore, there is an urgent clinical unmet need for better prognostication strategies, innovative therapies and significant improvement of the management of the individual patients. In this review, we summarize available studies on molecular prognostic markers and markers predictive of response to standard therapies as well as newly proposed drug targets in sporadic ACC. We include in vitro studies and available clinical trials, focusing on alterations at the DNA, RNA and epigenetic levels. We also discuss the potential of biomarkers to be implemented in a clinical routine workflow for improved ACC patient care.
Original languageEnglish
JournalClinical Endocrinology
Early online date8 Nov 2021
Publication statusE-pub ahead of print - 8 Nov 2021


  • adrenocortical cancer
  • biomarkers
  • precision medicine
  • prognosis
  • targeted treatment


Dive into the research topics of 'The role of molecular profiling in adrenocortical carcinoma'. Together they form a unique fingerprint.

Cite this